Activation of p53 pathway by Nutlin-3a inhibits the expression of the therapeutic target α5 integrin in colon cancer cells

Cancer Letters

Volumn 336, Issue 2, 2013, Pages 307-318

  Janouskova, Hana ^a,b   Ray, Anne Marie ^a   Noulet, Fanny ^a   Lelong Rebel, Isabelle ^a   Choulier, Laurence ^a   Schaffner, Florence ^a   Lehmann, Maxime ^a   Martin, Sophie ^a   Teisinger, Jan ^b   Dontenwill, Monique ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

Colon cancer; Integrin 5 1; Nutlin 3a; p53; RITA

Indexed keywords

5,5' (2,5 FURANDIYL) BIS 2 THIOPHENEMETHANOL; ALPHA5 INTEGRIN; NUTLIN 3; PROTEIN P53; SMALL INTERFERING RNA; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5;

ARTICLE; CANCER CELL; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; HCT116 CELLS; HUMANS; IMIDAZOLES; INTEGRIN ALPHA5; MOLECULAR TARGETED THERAPY; PIPERAZINES; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84879783461     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.03.018     Document Type: Article

References (41)

1. Kanwar S.S., Poolla A., Majumdar A.P. Regulation of colon cancer recurrence and development of therapeutic strategies. World J. Gastrointest. Pathophysiol. 2012, 3:1-9.
2. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10:9-22.
3. Karmakar S., Mukherjee R. Integrin receptors and ECM proteins involved in preferential adhesion of colon carcinoma cells to lung cells. Cancer Lett. 2003, 196:217-227.
4. Fujita S., Watanabe M., Kubota T., Teramoto T., Kitajima M. Alteration of expression in integrin beta 1-subunit correlates with invasion and metastasis in colorectal cancer. Cancer Lett. 1995, 91:145-149.
5. Gong J., Wang D., Sun L., Zborowska E., Willson J.K., Brattain M.G. Role of α5β1 integrin in determining malignant properties of colon carcinoma cells. Cell Growth Differ. 1997, 8:83-90.
6. Toquet C., Colson A., Jarry A., Bezieau S., Volteau C., Boisseau P., Merlin D., Laboisse C.L., Mosnier J.F. ADAM15 to α5β1 integrin switch in colon carcinoma cells: a late event in cancer progression associated with tumor dedifferentiation and poor prognosis. Int. J. Cancer 2012, 130:278-287.
7. Koike T., Kimura N., Miyazaki K., Yabuta T., Kumamoto K., Takenoshita S., Chen J., Kobayashi M., Hosokawa M., Taniguchi A., Kojima T., Ishida N., Kawakita M., Yamamoto H., Takematsu H., Suzuki A., Kozutsumi Y., Kannagi R. Hypoxia induces adhesion molecules on cancer cells: a missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc. Natl. Acad. Sci. USA 2004, 101:8132-8137.
8. Anderson J.A., Grabowska A.M., Watson S.A. PTHrP increases transcriptional activity of the integrin subunit α5. Br. J. Cancer 2007, 96:1394-1403.
9. Nam E.H., Lee Y., Park Y.K., Lee J.W., Kim S. ZEB2 upregulates integrin α5 expression through cooperation with Sp1 to induce invasion during epithelial-mesenchymal transition of human cancer cells. Carcinogenesis 2012, 33:563-571.
10. Murillo C.A., Rychahou P.G., Evers B.M. Inhibition of α5 integrin decreases PI3K activation and cell adhesion of human colon cancers. Surgery 2004, 136:143-149.
11. Stoeltzing O., Liu W., Reinmuth N., Fan F., Parry G.C., Parikh A.A., McCarty M.F., Bucana C.D., Mazar A.P., Ellis L.M. Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer 2003, 104:496-503.
12. Dia V.P., Gonzalez de Mejia E. Lunasin potentiates the effect of oxaliplatin preventing outgrowth of colon cancer metastasis, binds to α5β1 integrin and suppresses FAK/ERK/NF-kappaB signaling. Cancer Lett. 2011, 313:167-180.
13. Levine A.J., Oren M. The first 30years of p53: growing ever more complex. Nat. Rev. Cancer 2009, 9:749-758.
14. Robles A.I., Harris C.C. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb. Perspect. Biol. 2010, 2:a001016.
15. Iacopetta B., Russo A., Bazan V., Dardanoni G., Gebbia N., Soussi T., Kerr D., Elsaleh H., Soong R., Kandioler D., Janschek E., Kappel S., Lung M., Leung C.S., Ko J.M., Yuen S., Ho J., Leung S.Y., Crapez E., Duffour J., Ychou M., Leahy D.T., O'Donoghue D.P., Agnese V., Cascio S., Di Fede G., Chieco-Bianchi L., Bertorelle R., Belluco C., Giaretti W., Castagnola P., Ricevuto E., Ficorella C., Bosari S., Arizzi C.D., Miyaki M., Onda M., Kampman E., Diergaarde B., Royds J., Lothe R.A., Diep C.B., Meling G.I., Ostrowski J., Trzeciak L., Guzinska-Ustymowicz K., Zalewski B., Capella G.M., Moreno V., Peinado M.A., Lonnroth C., Lundholm K., Sun X.F., Jansson A., Bouzourene H., Hsieh L.L., Tang R., Smith D.R., Allen-Mersh T.G., Khan Z.A., Shorthouse A.J., Silverman M.L., Kato S., Ishioka C. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann. Oncol. 2006, 17:842-847.
16. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. The Cancer Genome Atlas Research Network (Collaboration).
17. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
18. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
19. Rigatti M.J., Verma R., Belinsky G.S., Rosenberg D.W., Giardina C. Pharmacological inhibition of mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells. Mol. Carcinog. 2011, 51:363-378.
20. Hori T., Kondo T., Kanamori M., Tabuchi Y., Ogawa R., Zhao Q.L., Ahmed K., Yasuda T., Seki S., Suzuki K., Kimura T. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. Cancer Lett. 2010, 287:98-108.
21. Janouskova H., Maglott A., Leger D.Y., Bossert C., Noulet F., Guerin E., Guenot D., Pinel S., Chastagner P., Plenat F., Entz-Werle N., Lehmann-Che J., Godet J., Martin S., Teisinger J., Dontenwill M. Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma. Cancer Res. 2012, 72:3463-3470.
22. Heckmann D., Meyer A., Laufer B., Zahn G., Stragies R., Kessler H. Rational design of highly active and selective ligands for the α5β1 integrin receptor. ChemBioChem 2008, 9:1397-1407.
23. Martinkova E., Maglott A., Leger D.Y., Bonnet D., Stiborova M., Takeda K., Martin S., Dontenwill M. α5β1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int. J. Cancer 2010, 127:1240-1248.
24. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L.G., Masucci M., Pramanik A., Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 2004, 10:1321-1328.
25. Enge M., Bao W., Hedstrom E., Jackson S.P., Moumen A., Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009, 15:171-183.
26. Goodman S.L., Picard M. Integrins as therapeutic targets. Trends Pharmacol. Sci. 2012, 33:405-412.
27. Stupp R., Ruegg C. Integrin inhibitors reaching the clinic. J. Clin. Oncol. 2007, 25:1637-1638.
28. Adachi M., Taki T., Higashiyama M., Kohno N., Inufusa H., Miyake M. Significance of integrin α5 gene expression as a prognostic factor in node-negative non-small cell lung cancer. Clin. Cancer Res. 2000, 6:96-101.
29. Mitra A.K., Sawada K., Tiwari P., Mui K., Gwin K., Lengyel E. Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene 2011, 30:1566-1576.
30. O'Brien V., Frisch S.M., Juliano R.L. Expression of the integrin α5 subunit in HT29 colon carcinoma cells suppresses apoptosis triggered by serum deprivation. Exp. Cell Res. 1996, 224:208-213.
31. Lee J.W., Juliano R.L. α5β1 integrin protects intestinal epithelial cells from apoptosis through a phosphatidylinositol 3-kinase and protein kinase B-dependent pathway. Mol. Biol. Cell 2000, 11:1973-1987.
32. Ravizza R., Gariboldi M.B., Passarelli L., Monti E. Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin. BMC Cancer 2004, 4:92.
33. Pietrzak M., Puzianowska-Kuznicka M. P53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter. Biol. Chem. 2008, 389:383-393.
34. Qin L., Chen X., Wu Y., Feng Z., He T., Wang L., Liao L., Xu J. Steroid receptor coactivator-1 upregulates integrin α(5) expression to promote breast cancer cell adhesion and migration. Cancer Res. 2011, 71:1742-1751.
35. Gingras M.E., Masson-Gadais B., Zaniolo K., Leclerc S., Drouin R., Germain L., Guerin S.L. Differential binding of the transcription factors Sp1, AP-1, and NFI to the promoter of the human α5 integrin gene dictates its transcriptional activity. Invest Ophthalmol. Vis. Sci. 2009, 50:57-67.
36. Kracikova M., Akiri G., George A., Sachidanandam R., Aaronson S.A. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ. 2013.
37. Grinkevich V.V., Nikulenkov F., Shi Y., Enge M., Bao W., Maljukova A., Gluch A., Kel A., Sangfelt O., Selivanova G. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009, 15:441-453.
38. Ray R.M., Bhattacharya S., Johnson L.R. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Apoptosis 2011, 16:35-44.
39. Valentine J.M., Kumar S., Moumen A. A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation. BMC Cancer 2011, 11:79.
40. Di Conza G., Buttarelli M., Monti O., Pellegrino M., Mancini F., Pontecorvi A., Scotlandi K., Moretti F. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells. Mol. Cancer Ther. 2012, 11:1247-1256.
41. Shin J.S., Ha J.H., He F., Muto Y., Ryu K.S., Yoon H.S., Kang S., Park S.G., Park B.C., Choi S.U., Chi S.W. Structural insights into the dual-targeting mechanism of Nutlin-3. Biochem. Biophys. Res. Commun. 2012, 420:48-53.